Page 95 - 《中国药房》2025年15期

tion in hematopoietic stem cell transplantation patients in [16] 马瑞，何云，王慧芳，等. 来特莫韦预防单倍体造血干细
Taiwan[J]. J Microbiol Immunol Infect，2024，57（3）： 胞移植后巨细胞病毒感染的临床分析[J]. 中华内科杂
365-374. 志，2023，62（7）：826-832.
[ 5 ] QIU Y L，ZHANG Y J，TENG M M，et al. Efficacy， [17] EINSELE H，LJUNGMAN P，BOECKH M. How I treat
safety，and cost-effectiveness analysis of antiviral agents CMV reactivation after allogeneic hematopoietic stem cell
for cytomegalovirus prophylaxis in allogeneic hematopoie- transplantation[J]. Blood，2020，135（19）：1619-1629.
tic stem cell transplantation recipients[J]. Transplantation， [18] PÉREZ A B，SANTOS BRAVO M，VIDAL-VERDÚ E，
2024，108（4）：1021-1032. et al. Real-life experience in two cases of secondary pro‐
[ 6 ] RUSSO D，SCHMITT M，PILORGE S，et al. Efficacy and phylaxis with letermovir for CMV infection in solid organ
safety of extended duration letermovir prophylaxis in re‐ transplantation[J]. Microbiol Spectr，2023，11（6）：e0163023.
cipients of haematopoietic stem-cell transplantation at risk [19] OGONEK J，KRALJ JURIC M，GHIMIRE S，et al. Im‐
of cytomegalovirus infection：a multicentre，randomised， mune reconstitution after allogeneic hematopoietic stem
double-blind，placebo-controlled，phase 3 trial[J]. Lancet cell transplantation[J]. Front Immunol，2016，7：507.
Haematol，2024，11（2）：e127-e135. [20] ROGERS R，SAHARIA K，CHANDORKAR A，et al.
[ 7 ] KIM E S. Letermovir：first global approval[J]. Drugs， Clinical experience with a novel assay measuring cyto‐
2018，78（1）：147-152. megalovirus （CMV）-specific CD4 and CD8 T-cell im‐
+
+
[ 8 ] MARTY F M，LJUNGMAN P，CHEMALY R F，et al. munity by flow cytometry and intracellular cytokine staining
Letermovir prophylaxis for cytomegalovirus in to predict clinically significant CMV events[J]. BMC
hematopoietic-cell transplantation[J]. N Engl J Med， Infect Dis，2020，20（1）：58.
2017，377（25）：2433-2444. [21] GAO X N，LIN J，WANG L J，et al. Risk factors and asso‐
[ 9 ] OHMOTO A，FUJI S. Letermovir for cytomegalovirus in‐ ciations with clinical outcomes of cytomegalovirus reacti‐
fection in allogeneic hematopoietic stem-cell transplanta‐ vation after haploidentical versus matched-sibling unma‐
tion：tips and notes for effective use in clinical practice[J]. nipulated PBSCT in patients with hematologic malignan‐
Expert Rev Anti Infect Ther，2024，22（4）：169-178. cies[J]. Ann Hematol，2020，99（8）：1883-1893.
[10] MASSOUD R，GAGELMANN N，FRITZSCHE-FRIEDLAND [22] CHANG Y J，WANG Y，XU L P，et al. Haploidentical do‐
U，et al. Comparison of immune reconstitution between nor is preferred over matched sibling donor for pre-
anti-T-lymphocyte globulin and posttransplant cyclophos‐ transplantation MRD positive ALL：a phase 3 genetically
phamide as acute graft-versus-host disease prophylaxis in randomized study[J]. J Hematol Oncol，2020，13（1）：27.
allogeneic myeloablative peripheral blood stem cell trans‐ [23] CHANG Y J，WU D P，LAI Y R，et al. Antithymocyte
plantation[J]. Haematologica，2022，107（4）：857-867. globulin for matched sibling donor transplantation in pa‐
[11] ZUHAIR M，SUZANNE A SMIT G，WALLIS G，et al. tients with hematologic malignancies：a multicenter，open-
Estimation of the worldwide seroprevalence of cytomega‐ label，randomized controlled study[J]. J Clin Oncol，2020，
lovirus：a systematic review and meta-analysis[J]. Rev 38（29）：3367-3376.
Med Virol，2019，29（3）：e2034. [24] ZHANG Y Y，MO W J，ZUO Y Y，et al. Comparable sur‐
[12] YONG M K，SHIGLE T L，KIM Y J，et al. American vival outcome between transplantation from haploidenti‐
Society for Transplantation and Cellular Therapy series： cal donor and matched related donor or unrelated donor
#4-cytomegalovirus treatment and management of resis‐ for severe aplastic anemia patients aged 40 years and
tant or refractory infections after hematopoietic cell trans‐ older：a retrospective multicenter cohort study[J]. Clin
plantation[J]. Transplant Cell Ther，2021，27（12）：957-967. Transplant，2020，34（3）：e13810.
[13] SOLANO C，VÁZQUEZ L，GIMÉNEZ E，et al. Cyto‐ [25] YEH T J，YANG C I，HUANG C T，et al. Revisit of the
megalovirus DNAemia and risk of mortality in allogeneic association between cytomegalovirus infection and invasive
hematopoietic stem cell transplantation：analysis from the fungal infection after allogeneic hematopoietic stem cell
Spanish Hematopoietic Transplantation and Cell Therapy transplantation：a real-world analysis from a high CMV se‐
Group[J]. Am J Transplant，2021，21（1）：258-271. roprevalence area[J]. J Fungi （Basel），2022，8（4）：408.
[14] MALAGOLA M，POLLARA C，POLVERELLI N，et al. [26] TONG J，SUN Z M，LIU H L，et al. Risk factors of CMV
Advances in CMV management：a single center real-life infection in patients after umbilical cord blood transplanta‐
experience[J]. Front Cell Dev Biol，2020，8：534268. tion：a multicenter study in China[J]. Chin J Cancer Res，
[15] ZAMORA D，DUKE E R，XIE H，et al. Cytomegalovirus- 2013，25（6）：695-703.
specific T-cell reconstitution following letermovir prophy‐ （收稿日期：2025-02-12 修回日期：2025-06-15）
laxis after hematopoietic cell transplantation[J]. Blood， （编辑：舒安琴）
2021，138（1）：34-43.

中国药房 2025年第36卷第15期 China Pharmacy 2025 Vol. 36 No. 15 · 1909 ·